Search the Newsreel

A Closer Look at Vicinity Centres’ (ASX:VCX) Latest Market Move and Property Position

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

Cinemark Holdings (CNK) Is Up 8.6% After Record Spider-Man Weekend And Q2 Results - Has The Bull Case Changed?

Cinemark Holdings (CNK) saw an 8.6% increase after a record-breaking "Spider-Man: Brand New Day" weekend and strong Q2 2026 results, with revenue reaching US$1,086.4 million and net income US$139.4 million. While these results bolster the short-term bull case, they also highlight the company's reliance …

Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the …

CX Institutional Acquires 31,548 Shares of Cincinnati Financial Corporation $CINF

CX Institutional significantly increased its stake in Cincinnati Financial Corporation (NASDAQ:CINF) by 1,405.9% in the second quarter, purchasing an additional 31,548 shares. This brings their total holdings to 33,792 shares, valued at approximately $6.26 million. Despite missing the consensus earnings estimate for the quarter, …

Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026

Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments and increased its 2026 spending forecast to $2.1 billion to $2.2 billion to advance late-stage oncology programs and prepare for a potential first product launch. The company's lead drug, daraxonrasib, cleared a …

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results

Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains …

Revolution Medicines Q2 Net Loss Widens

Revolution Medicines reported a significant widening of its net loss in Q2, increasing to $111.4 million from $70.8 million year-over-year, largely due to increased research and development expenses. Despite the loss, the company exceeded revenue expectations with $9.3 million, up from $2.1 million in …

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. …

Revolution Medicines falls on second quarter earnings miss

Revolution Medicines (NASDAQ:RVMD) reported a significant earnings miss for the second quarter, with a loss of -$3.06 per share against an estimated -$1.96. The net loss for the quarter reached $644.4 million, impacted by a non-cash charge related to an acquisition. Despite the financial …

Cintas Corp. stock underperforms Wednesday when compared to competitors

Cintas Corp. (CTAS) shares fell by 1.10% on Wednesday, closing at $201.40, marking its fifth consecutive day of losses. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the S&P 500 Index declining. The stock's performance was …

Star Sports Medicine Sets Board Meeting to Approve Interim Results and Consider Dividend

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines announced its Q2 2026 financial results and provided an update on corporate progress, highlighting the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and the rapid implementation of an Expanded Access Program. The company also reported encouraging new combination …

Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan

Editas Medicine's CFO, Amy Parison, sold 678 shares of common stock at $2.58 per share on August 3, 2026. This transaction was executed under a pre-established Rule 10b5-1 plan to cover tax withholding obligations from restricted stock units that vested on August 1, 2026, …

Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M

Editas Medicine reported a Q2 2026 net loss of $18.2 million, significantly trimmed from $53.2 million a year prior, and saw collaboration revenues increase to $11.9 million. The company's cash, cash equivalents, and marketable securities totaled $211.6 million as of June 30, 2026, boosted …

Cintas Announces Executive Leadership Restructuring

Cintas, a Counselor Top 40 distributor, has restructured its executive leadership by separating the roles of CEO and President. Todd Schneider will remain CEO, while Jim Rozakis, a 27-year veteran of the company, has been promoted to President and COO. This move is intended …

Praxis Precision earnings on deck as commercialization nears

Praxis Precision Medicines Inc. is set to report second-quarter results, with investors focused on cash burn and commercial readiness as the company awaits two key FDA drug approval decisions. Analysts have a strong buy rating with significant upside potential. The company's cash runway and …

Hiroshima Bank selects nCino for lending overhaul

Hiroshima Bank has chosen nCino's AI banking platform to modernize its consumer lending operations, including mortgage loans. This initiative is part of the bank's Mid-Term Management Plan 2024, aiming to improve sales processes and operational efficiency. The integration of nCino will move the entire …

Cinemark (CNK) Upgraded to Strong Buy: Here's What You Should Know

Investors might want to bet on Cinemark Holdings (CNK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock …

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Generate Biomedicines (NASDAQ: GENB) is one of the top five largest holdings of Nvidia (NASDAQ: NVDA), run by CEO Jensen Huang. Let that sink in for a moment. The largest publicly traded company by market capitalization has roughly $10.4 million invested in a clinical-stage …

Cincinnati Financial (CINF) Beat On Earnings, Is The Stock Fully Priced?

Praxis Precision Medicines Q2 2026 Earnings Preview

* Praxis Precision Medicines (PRAX [https://seekingalpha.com/symbol/PRAX]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is -$3.69 [https://seekingalpha.com/symbol/PRAX/earnings/estimates] (-11.5% Y/Y) and the consensus Revenue Estimate is $0M * Over the last 3 months, EPS …

nCino (NCNO) insider Jeanette Sellers files Form 144 to sell 1,536 shares

nCino, Inc. insider Jeanette E. Sellers has filed a Form 144 to sell 1,536 shares of common stock, valued at $29,998.08, through Fidelity Brokerage Services on NASDAQ. These shares are part of restricted stock that vested on August 1, 2026, received as compensation. The …

Revolution Medicines stock hits all-time high of 195.48 USD By Investing.com

Revolution Medicines Inc. (RVMD) has reached an all-time stock high of $195.48, reflecting significant investor confidence with a 1-year price return of 403.93%. Despite an InvestingPro analysis suggesting the stock is overvalued, analysts from UBS, Mizuho, Wedbush, and Truist Securities have raised price targets …

nCino (NCNO) insider Sean Desmond plans 11,815-share stock sale after equity vesting

nCino (NCNO) insider Sean Desmond has filed a Form 144 notice to sell 11,815 shares of common stock, valued at approximately $231,460.61. This proposed sale includes shares from restricted stock vesting and a stock option exercise, both occurring in early August 2026. Desmond has …

Everest Medicines Ltd. Revenue Breakdown – HKEX:1952

Cintas splits CEO and president roles, promotes 27-year veteran to new position

Cintas Corp. has announced a change in its C-suite structure, splitting the roles of CEO and president. This move involves promoting a 27-year veteran executive to the newly designated president position. The Cincinnati Business Courier reported on this development.

Sei Investments Co. Sells 8,979 Shares of Cincinnati Financial Corporation $CINF

Sei Investments Co. reduced its stake in Cincinnati Financial Corporation (NASDAQ:CINF) by 18.3% in the first quarter, selling 8,979 shares and retaining 40,200 shares valued at $6.33 million. Despite missing quarterly earnings estimates, the company reported strong revenue and analysts maintain a "Moderate Buy" …

Lipocine Q2 2026 earnings: Missing license revenue drives top-line decline

Lipocine (NASDAQ: LPCN) reported a significant decline in Q2 2026 revenue to $190,099, primarily due to the absence of license revenue from the prior year, though TLANDO royalties increased. The company's net loss widened to $2.6 million, and attention is now focused on an …

Revolution Medicines (Nasdaq: RVMD) widens loss as R&D spend and financing surge

Revolution Medicines RVMD Q2 2026: FDA Acceptance and a $151M Charge Explained

Beone Medicines Ag Raises Earnings Guidance for 2026

TYK Medicines Schedules Board Meeting to Approve Interim Results and Consider Dividend

Editas Medicine (EDIT) Earnings Date and Reports 2026 $EDIT

Editas Medicine earnings beat by $0.12, revenue topped estimates

Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News